BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31924333)

  • 1. Declining brachytherapy utilization for cervical cancer patients - Have we reversed the trend?
    Schad MD; Patel AK; Glaser SM; Balasubramani GK; Showalter TN; Beriwal S; Vargo JA
    Gynecol Oncol; 2020 Mar; 156(3):583-590. PubMed ID: 31924333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disparities in the management and outcome of cervical cancer in the United States according to health insurance status.
    Churilla T; Egleston B; Dong Y; Shaikh T; Murphy C; Mantia-Smaldone G; Chu C; Rubin S; Anderson P
    Gynecol Oncol; 2016 Jun; 141(3):516-523. PubMed ID: 27012428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements.
    Gill BS; Lin JF; Krivak TC; Sukumvanich P; Laskey RA; Ross MS; Lesnock JL; Beriwal S
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1083-90. PubMed ID: 25216857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer.
    Korenaga TK; Yoshida EJ; Pierson W; Chang J; Ziogas A; Swanson ML; Chapman JS; Sinha S; Chen LM
    Gynecol Oncol; 2022 Feb; 164(2):348-356. PubMed ID: 34865860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of marital status on receipt of brachytherapy and survival outcomes in locally advanced cervical cancer.
    Huynh-Le MP; Klapheke A; Cress R; Mell LK; Yashar CM; Einck JP; Mundt AJ; Mayadev JS
    Brachytherapy; 2019; 18(5):612-619. PubMed ID: 31153760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of sociodemographic and baseline patient characteristic differences in cervical cancer patients treated with either external beam or brachytherapy boost.
    Lu DJ; Atkins KM; Small W; Kamrava M
    Brachytherapy; 2022; 21(1):22-28. PubMed ID: 34895839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Insurance Status on Radiation Treatment Modality Selection Among Potential Candidates for Prostate, Breast, or Gynecologic Brachytherapy.
    Grant SR; Walker GV; Koshy M; Shaitelman SF; Klopp AH; Frank SJ; Pugh TJ; Allen PK; Mahmood U
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):968-75. PubMed ID: 26452570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How might financial pressures have impacted brachytherapy? A proposed narrative to explain the declines in cervical and prostate brachytherapy utilization.
    Schad M; Kowalchuk R; Beriwal S; Showalter TN
    Brachytherapy; 2019; 18(6):780-786. PubMed ID: 31439465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated Trends in Cervical Cancer Brachytherapy Utilization and Disparities in the United States From 2004 to 2020.
    Colson-Fearon D; Han K; Roumeliotis MB; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2024 May; 119(1):154-162. PubMed ID: 38040060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base.
    Martin JM; Handorf EA; Kutikov A; Uzzo RG; Bekelman JE; Horwitz EM; Smaldone MC
    Cancer; 2014 Jul; 120(14):2114-21. PubMed ID: 24737481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic Body Radiation Therapy, Intensity-Modulated Radiation Therapy, and Brachytherapy Boost Modalities in Invasive Cervical Cancer: A Study of the National Cancer Data Base.
    OʼDonnell B; Shiao JC; Pezzi TA; Waheed N; Sharma S; Bonnen MD; Ludwig MS
    Int J Gynecol Cancer; 2018 Mar; 28(3):563-574. PubMed ID: 29324547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in the utilization of brachytherapy in cervical cancer in the United States.
    Han K; Milosevic M; Fyles A; Pintilie M; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):111-9. PubMed ID: 23849695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying disparities in brachytherapy delivery for locally advanced cervical cancer.
    Eakin A; Wairiri L; Stadtlander W; Bruegl A; Emerson J; Williamson C; Kahn J
    Brachytherapy; 2023; 22(4):461-467. PubMed ID: 37015846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High versus low-dose rate brachytherapy for cervical cancer.
    Patankar SS; Tergas AI; Deutsch I; Burke WM; Hou JY; Ananth CV; Huang Y; Neugut AI; Hershman DL; Wright JD
    Gynecol Oncol; 2015 Mar; 136(3):534-41. PubMed ID: 25575481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated Trends in the Utilization of Brachytherapy in Cervical Cancer in the United States: A Surveillance, Epidemiology, and End-Results Study.
    Han K; Colson-Fearon D; Liu ZA; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2024 May; 119(1):143-153. PubMed ID: 37951548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Explainable artificial intelligence analysis of brachytherapy boost receipt in cervical cancer during the COVID-19 era.
    Ladbury C; Eustace N; Kassardjian A; Amini A; Chen YJ; Wang E; Kohut A; Tergas A; Han E; Song M; Glaser S
    Brachytherapy; 2024; 23(3):237-247. PubMed ID: 38553406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in cervical cancer brachytherapy volume suggest case volume is not the primary driver of poor compliance rates with brachytherapy delivery for locally advanced cervical cancer.
    Trifiletti DM; Grover S; Libby B; Showalter TN
    Brachytherapy; 2017; 16(3):547-551. PubMed ID: 28336252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in insurance coverage for cancer patients receiving brachytherapy before and after enactment of the Affordable Care Act.
    Spiegel DY; Chino F; Moss H; Havrilesky LJ; Chino JP
    Brachytherapy; 2019; 18(1):115-121. PubMed ID: 30352751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FIGO stage IB1 cervical carcinoma: Place and principles of brachytherapy.
    Huertas A; Oldrini S; Nesseler JP; Courrech F; Rétif P; Charra-Brunaud C; Peiffert D
    Cancer Radiother; 2017 Apr; 21(2):155-163. PubMed ID: 28233697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.
    Strauss HG; Kuhnt T; Laban C; Puschmann D; Pigorsch S; Dunst J; Koelbl H; Haensgen G
    Strahlenther Onkol; 2002 Jul; 178(7):378-85. PubMed ID: 12163992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.